BB-K8

• Anti-bacterial Agents
• Aminoglycosides
• ATC:D06AX12
• ATC:J01GB06
• ATC:S01AA21

• ANTIBIOTIC BB-K8
• Amicacin
• Amiglyde-V
• Amikacin Base
• Amikacin Dihydrate
• Amikacin Sulfate
• Amikacin [Usan:Ban:Inn]
• Amikacina [Inn-Spanish]
• Amikacine [Inn-French]
• Amikacinum [Inn-Latin]
• Amikavet
• Amikin
• BB-K8
• Briclin
• Novamin

• No information avaliable

C₂₂H₄₃N₅O₁₃

http://www.rxlist.com/cgi/generic3/amikacin.htm

BB-K8 MSDS

H. Kawaguchi, T. Naito, Ger. pat. 2,234,315; H. Kawaguchi et al., U.S. pat. 3,781,268 (both 1973 to Bristol-Myers)

585.603 g/mol

203-204 ^oC

1.85E+005 mg/L

Solid

-9.048

IM infusion; IM injection

For short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species.

Amikacin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Rapidly absorbed after intramuscular administration

No information avaliable

Enteric bacteria and other eubacteria